Quantcast

Latest Pertuzumab Stories

2014-04-04 23:36:36

Active research in breast cancer is producing novel targeted drugs at a rapid pace. Thousand Oaks, California (PRWEB) April 03, 2014 As the Cancer society continues research for breast cancer, several options have emerged. Of these options three drugs have been approved by the FDA for usage as treatment and no one is more excited than Dr. Mai Brooks. Perjeta (pertuzumab) In September 2013, the FDA approved Perjeta for use in combination with Herceptin (trastuzumab) and docetaxel for the...

2013-12-14 23:00:56

MarketResearchReports.Biz announces addition of new report “Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth” to its database. Visit: http://www.marketresearchreports.biz/analysis-details/monoclonal-antibodies-market-in-gastric-and-esophageal-cancers-to-2019-crowded-late-stage-pipelines-and-favorable-market-conditions-encourage-robust-growth. Albany, NY (PRWEB) December 14, 2013...

2013-03-08 23:04:38

A recent FDA-approved combination of therapies used to target HER2-positive breast cancer does not lead to increased cardiac problems for patients, but doctors should regularly perform cardiac monitoring on their cancer patients until additional long-term cardiac safety data become available, according to the first phase III study of the combined treatments. The study, published in The Oncologist, was led by Dr. Sandra M. Swain, MD, Medical Director of the Washington Cancer Institute at...

2011-12-08 12:53:09

Adding pertuzumab to a combination of trastuzumab and docetaxel chemotherapy extended progression-free survival by a median of 6.1 months in patients with metastatic HER2-positive breast cancer compared with patients who received the combination therapy with placebo. Researchers conducted an international phase 3, double-blind, randomized trial, known as CLEOPATRA (CLinical Evaluation Of Pertuzumab And TRAstuzumab), in which they randomly assigned 808 patients to receive trastuzumab and...

2010-02-24 07:00:00

WALTHAM, Mass., Feb. 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2018, Sanofi-Aventis's BSI-201 will garner sales of $1.7 billion in the triple negative breast cancer drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Owing to the improvement in overall survival rates it has demonstrated in clinical trials and the need for novel targeted...

2010-02-01 08:26:00

WALTHAM, Mass., Feb. 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the second-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, a targeted treatment that increases the median progression-free survival relative to a regimen of GlaxoSmithKline/Nippon Kayaku's Tykerb/Tyverb and Roche/Chugai's Xeloda would earn similar patient share in the...

2009-02-11 07:00:00

Genentech/Roche/Chugai's Drug in Combination With Herceptin and Taxotere Will Become Decision Resources Gold Standard Regimen by 2017, According to a New Report from Decision Resources WALTHAM, Mass., Feb. 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that if Genentech/Roche/Chugai's Herceptin is approved in combination with emerging therapies, it will be in a position to retain patient share from...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related